Pregabalin Capsule
Product Images NDC 71335-1300

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1300). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lbl7133513002

Label for Pregabalin 50 mg (CV) capsules, repackaged by Bryant Ranch Prepack, Burbank, CA. The label indicates comparison to Lyrica 50 mg capsules by Laurus Labs Limited. It specifies storage at room temperature (20°-25°C) and cautions to keep drugs out of reach of children. The package includes a barcode and NDC 71335-1300.*

FDA Label Image

Pregabalinchemistrystructure (Pregabalin Chem Structure)

Chemical structure diagram of pregabalin, showing its carbon backbone with an amino group (NH2) and a carboxyl group (CO2H) attached, consistent with the molecular representation of the active ingredient pregabalin.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A mathematical formula describing creatinine clearance (CLCr) calculation, including variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplier of 0.85 for female patients. This formula is typically used in pharmacokinetic assessments.*

FDA Label Image

Pregabalinfig1 (Pregabalin Fig 01)

A line graph depicting percent of patients improved against percent improvement in pain from baseline for Pregabalin at doses of 200 mg, 100 mg, 25 mg three times a day, and placebo. The vertical axis represents the percent of patients improved, ranging from 0 to 100%, while the horizontal axis shows percent improvement in pain from baseline, ranging from 0 to 100%.*

FDA Label Image

Pregabalinfig2 (Pregabalin Fig 02)

A line graph depicting the percent of patients improved against percent improvement in pain from baseline for Pregabalin 100 mg three times a day versus placebo. The graph shows higher patient improvement percentages for Pregabalin compared to placebo across varying levels of pain improvement.*

FDA Label Image

Pregabalinfig3 (Pregabalin Fig 03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 300 mg two times a day, Pregabalin 150 mg two times a day, Pregabalin 75 mg two times a day, and placebo. The x-axis represents percent improvement in pain, and the y-axis represents the percent of patients improved.*

FDA Label Image

Pregabalinfig4 (Pregabalin Fig 04)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows greater improvement in pain for both Pregabalin doses compared to placebo, with Pregabalin 200 mg having the highest percent of patients improved across different levels of pain improvement.*

FDA Label Image

Pregabalinfig5 (Pregabalin Fig 05)

This chart compares the percentage of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph shows lines representing each group across varying levels of pain improvement.*

FDA Label Image

Pregabalinfig6 (Pregabalin Fig 06)

A bar graph showing responder rates (%) for two studies, Study E1 and Study E3. The x-axis lists treatment groups including placebo and various doses of pregabalin (50 mg/day, 150 mg/day, 300 mg/day, 600 mg/day), with respondent rate percentages on the y-axis ranging from 0% to 60%. The graph visually compares responder rates between the placebo group and different pregabalin dosage groups.*

FDA Label Image

Pregabalinfig7 (Pregabalin Fig 07)

A line chart depicting seizure reduction (median % change from baseline) on the Y-axis versus dose in mg/day on the X-axis. The chart compares four different studies (E1 BD, E2 TID, E3 BD, E3 TID) with distinct markers, illustrating increasing seizure reduction with higher doses. Significant p-values are noted for different dose points.*

FDA Label Image

Pregabalinfig8 (Pregabalin Fig 08)

A Kaplan-Meier-type curve chart showing percent of patients improved on the y-axis and percent improvement in pain from baseline on the x-axis. The graph compares four groups: Pregabalin 600 mg daily dose, 450 mg daily dose, 300 mg daily dose, and a placebo. Lines illustrate the proportion of patients achieving various levels of pain improvement under each treatment.*

FDA Label Image

Pregabalinfig9 (Pregabalin Fig 09)

A Kaplan-Meier survival curve graph showing the estimated percentage of subjects without LTR over a period of 180 days. Two lines represent treatment with Pregabalin and Placebo, with Pregabalin showing a higher estimated percentage of subjects without LTR throughout the study duration.*

FDA Label Image

Pregabalinfig10 (Pregabalin Fig 10)

A line graph comparing the percentage of subjects improved over baseline to week 12 between Pregabalin and Placebo groups. The x-axis shows percent improvement from baseline, ranging from 0 to 100, and the y-axis represents the percent of subjects improved, also from 0 to 100. Pregabalin shows a higher percentage of subjects improved compared to Placebo across the improvement scale.*

FDA Label Image

Pregabalinfig11 (Pregabalin Fig 11)

A line chart comparing the percent of subjects improved between Pregabalin and Placebo from baseline to Week 16 BOCF. The X-axis shows percentage improvement from 0 to 100%, and the Y-axis shows the percent of subjects improved, indicating higher improvement percentages for Pregabalin compared to Placebo across the range.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.